several prescription bottles filled with colorfu pills and capsules, shot from above on white background with soft white drop shadowAccording to, “Dublin-based Allergan has entered into an agreement with AstraZeneca to develop and commercialize a fixed-dose antibiotic formulation currently in Phase II study. The financial terms of the agreement were not detailed, though Allergan will maintain rights to commercialization in the U.S. and Canada while AstraZeneca will hold commercialization rights in all other global markets.”  For more information on this development deal, please visit: